Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

BACKGROUND: Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrero-García, Luis D., del Mar Maldonado, Maria, Medina-Velázquez, Julia, Troche-Torres, Angel L., Velazquez, Luis, Grafals-Ruiz, Nilmary, Dharmawardhane, Suranganie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170972/
https://www.ncbi.nlm.nih.gov/pubmed/34074257
http://dx.doi.org/10.1186/s12885-021-08366-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170972/
https://www.ncbi.nlm.nih.gov/pubmed/34074257
http://dx.doi.org/10.1186/s12885-021-08366-7

Ejemplares similares